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Background: A recent study by Mishra and Hoon identified B-type natriuretic peptide (BNP) as an important
peptide for itch transmission and proposed that BNP activates spinal natriuretic peptide receptor-A (NPRA) expressing
neurons, which release gastrin releasing peptide (GRP) to activate GRP receptor (GRPR) expressing neurons to relay itch
information from the periphery to the brain (Science 340:968–971, 2013). A central premise for the validity of this novel
pathway is the absence of GRP in the dorsal root ganglion (DRG) neurons. To this end, they showed that Grp mRNA in
DRG neurons is either absent or barely detectable and claimed that BNP but not GRP is a major neurotransmitter for
itch in pruriceptors. They showed that NPRA immunostaining is perfectly co-localized with Grp-eGFP in the spinal cord,
and a few acute pain behaviors in Nppb−/− mice were tested. They claimed that BNP is an itch-selective peptide that
acts as the first station of a dedicated neuronal pathway comprising a GRP-GRPR cascade for itch. However, our studies,
along with the others, do not support their claims.
Findings: We were unable to reproduce the immunostaining of BNP and NPRA as shown by Mishra and Hoon. By
contrast, we were able to detect Grp mRNA in DRGs using in situ hybridization and real time RT-PCR. We show
that the expression pattern of Grp mRNA is comparable to that of GRP protein in DRGs. Pharmacological and
genetic blockade of GRP-GRPR signaling does not significantly affect intrathecal BNP-induced scratching
behavior. We show that BNP inhibits inflammatory pain and morphine analgesia.
Conclusions: Accumulating evidence demonstrates that GRP is a key neurotransmitter in pruriceptors for mediating
histamine-independent itch. BNP-NPRA signaling is involved in both itch and pain and does not function upstream of
the GRP-GRPR dedicated neuronal pathway. The site of BNP action in itch and pain and its relationship with GRP remain
to be clarified.
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Identification of novel itch mediators in sensory neurons
and in the spinal cord and elucidation of the molecular
and cellular circuitry have become a new and exciting
frontier for the past several years. As many itch mediators
(neuropeptides, receptors and channels etc.) have been
implicated in itch transmission, conflicting results and
confusion emerge. Gastrin releasing peptide (GRP) is a* Correspondence: chenz@wustl.edu
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stated.neuropeptide expressed in primary afferents and is
necessary for relaying non-histaminergic itch from the
skin to the spinal cord [1-4]. For several decades, the
availability of the antibody against the highly con-
served nine amino acids in the C terminus of GRP/
bombesin across species has enabled the demonstration
of expression of GRP in primary afferents of rat, mouse,
cat, monkey and human. Using the anti-GRP or bombesin
antibody, the percentage of GRP+ cells has been consist-
ently estimated to be around 5–8% in dorsal root gan-
glion (DRG) neurons and 12% in trigeminal ganglia (TG)
neurons of rodents [2,5-14]. Several groups have used
dorsal root rhizotomy to examine the origin of GRP+This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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have consistently found that the majority of GRP+ fibers
are derived from primary afferents [2,4,7-9,15], with only
one exception [16]. The earlier findings on the origin of
GRP+ fibers have been reviewed previously [1,17]. In
addition, neonatal capsaicin treatment dramatically de-
pleted GRP+ fibers in the spinal cord, which supported the
notion that the source of GRP is from primary afferents
[18]. It is important to note that the specificity of the anti-
GRP antibody has been repeatedly confirmed using Grp−/−
mice [4,19] and by an antigen absorption approach [16],
the latter of which was first performed more than 30
years ago [8]. Importantly, several studies found that
GRP expression was markedly enhanced in primary
afferents in mice, monkeys and patients with various
chronic itch conditions [4,11-13], matching an up-
regulation of GRPR in the spinal cord [4,12]. Those
studies support a physiological role of GRP in primary
afferents. On the other hand, the specific expression of
Grp mRNA in lamina I of the spinal cord and a failure
to detect Grp mRNA in DRG neurons using in situ
hybridization (ISH) by some investigators have reig-
nited interests in spinal Grp expression [16]. To date,
little evidence exists to support that Grp mRNA in
lamina I of the spinal cord is in fact translated into GRP
protein because none of the GRP immunohistochemistry
studies after dorsal root rhizotomy have revealed the
neuronal cell body staining pattern that resembles that
of Grp mRNA in the spinal cord. It was speculated that
some of the residual GRP+ fiber staining in the spinal
cord after rhizotomy could be of descending origins
[8,9]. Moreover, an up-regulation of GRP protein in-
trinsic to the dorsal horn in the setting of chronic itch
was not detected [4], further arguing against the
physiological role of Grp mRNA in the spinal cord.
Additional evidence supporting the idea of activation
of postsynaptic GRPR by presynaptic GRP release has
also emerged. Potential synaptic contacts between
MrgprA3+ primary afferents and GRPR+ neurons were
demonstrated [20]. Electron microscopic analysis revealed
that GRP+ terminals contained large dense-core vesicles
that formed synaptic contacts with a few dendrites of
dorsal horn neurons [15]. Despite a large body of lit-
erature that demonstrated the presence of GRP pro-
tein in DRGs and primary afferents, a recent study by
Mishra and Hoon attempted to show a lack of Grp
mRNA in sensory neurons and proposed that B-type
natriuretic peptide (BNP), rather than GRP, is a major
neuropeptide in primary afferents for itch transmission
[21]. Further, they proposed that BNP activates natriuretic
peptide receptor-A (NPRA) expressing neurons in the
spinal cord, which in turn release GRP to activate
GRPR+ neurons. In this report, we present the data
that do not support their conclusions.NPRA and BNP expression in DRGs and spinal cord
BNP, which is encoded by the Nppb gene, and its receptor
NPRA that is encoded by Npr1 have been studied for
decades [22] and recently implicated in itch transmission
[21]. Using Grp-eGFP BAC-transgenic mice, Mishra and
Hoon reported a perfect co-localization of NPRA protein
and eGFP expression in lamina I of the spinal cord using
a LifeSpan antibody for NPRA. However, this striking
image is inconsistent with two additional findings: 1)
they showed that Npr1+ cells are scattered throughout the
dorsal horn, whereas several studies including our own
have demonstrated that Grp mRNA is largely restricted to
lamina I [23-25]; 2) with an Abcam antibody, no laminae
I-II-restricted NPRA+ immunostaining was detected after
dorsal root rhizotomy to remove intense NPRA+ fibers in
the dorsal horn of rats [26]. Indeed, immunostaining using
the two different antibodies shows comparable widespread
NPRA+ expression pattern in DRG neurons (Figure 1A,
1B), in accordance with studies in mice and in rats [26,27].
However, in the spinal cord no lamina-specific NPRA+
staining was observed using the LifeSpan antibody
(Figure 1C) as reported by Mishra and Hoon, while an
Abcam antibody reveals intense NPRA+ primary fibers
(Figure 1D), reminiscent of the finding in rat [26]. Our
comparative studies suggest that the Abcam NPRA
antibody may better recapitulate endogenous expression
of NPRA in sensory neurons.
Mishra and Hoon showed BNP immunostaining in
mouse DRG neurons [21]. Using the same antibody
(LifeSpan) and another BNP antibody from Santa Cruz,
however, we found satellite glial like pattern in DRGs
(Figure 1E, 1F). Using a different BNP antibody (Phoenix
Pharmaceuticals), another group recently found that BNP
immunostaining was similarly present in non-neuronal
cells and rarely detected in neuron-like cells in mouse
TGs [27], suggesting a possible involvement of peripheral
BNP in neuron-glia crosstalk. Although these results
are not consistent with ISH studies [21] in DRG neurons
nor with the data in rats [26], three BNP antibodies sup-
plied by different companies all showed non-neuronal
cell-like staining in DRGs or TGs of mice. In light of these
discrepancies, it will be helpful to verify the specificity of
BNP antibodies in Nppb−/− mice and to define whether
BNP protein is expressed in primary afferents.
Grp mRNA expression in DRG neurons
A central premise for the validity of the BNP-NPRA-
GRP-GRPR cascade proposed by Mishra and Hoon is a
lack of GRP in primary afferents. Although a specific GRP
antibody has eliminated the necessity for examining Grp
mRNA using ISH technique, single cell RT-PCR permits a
more precise assessment of co-expression of Grp mRNA
with other markers such as Trpv1 mRNA in a subset of


















NPRA (LifeSpan) NPRA (Abcam)
Figure 1 NPRA and BNP immunostaining in DRG neurons and spinal cord. A-D) NPRA immunostaining in mouse DRG (upper row) and
dorsal spinal cord (lower row) was performed with antibodies from LifeSpan BioSciences (A, C) and Abcam (B, D). The inset in (C) shows non-
specific signals that do not overlap with NeuN staining (green). E-F) BNP immunostaining in DRG using antibodies from LifeSpan Biosciences (E)
and Santa Cruz (F). Scale bars: 50 μm.
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pieces of evidence to dispute the presence of Grp mRNA
in DRGs [21]. First, they could not detect Grp mRNA
in DRGs using ISH. Unfortunately, Grp mRNA detection
in DRGs by ISH has remained a challenge for some inves-
tigators [16,21]. We have recently shown that BRAFNav1.8
mice represent a unique animal model for investigating
the mechanisms of chronic itch [4]. In BRAFNav1.8 mice,
the expression of a cohort of itch-related mediators
including GRP protein was markedly increased in DRGs,
which account for the development of spontaneous itch
in these mice [4]. Using ISH, we detected a few Grp+ cells
in wild-type (WT) DRGs, consistent with GRP immu-
nostaining pattern (Figure 2A). In contrast, many more
Grp+ cells were detected in DRGs of BRAFNav1.8 mice,
demonstrating enhanced Grp mRNA expression in the
setting of chronic itch (Figure 2A), consistent with
enhanced GRP protein expression as detected usinganti-GRP antibody [4]. These conflicting results indicate
that the sensitivity of ISH rests on multiple factors (e.g.
tissues, age of animals, perfusion method, the abundance
of transcripts, etc.). Concerning gene expression in DRGs
and spinal cord, it is not uncommon that mRNA or pro-
tein for some genes can be easily detected in one tissue
but not the other. Therefore, ISH procedure or immuno-
staining procedure has to be optimized and tailored to
specific cRNA probes/antibodies if the routine procedure
fails to work.
Second, Mishra and Hoon tried to minimize the pres-
ence of Grp mRNA by stating that they were unable to
detect more than “trace quantities” of Grp expression
in DRGs using a “sensitive quantitative” PCR assay [21].
However, “trace quantities” of Grp could be a sufficient
amount of mRNA to generate physiologically relevant
level of GRP that is necessary for GRPR activation in the


























































Figure 2 Expression of Grp mRNA in DRGs. A) Grp mRNA was detected in WT and BRAFNav1.8 DRGs using ISH. Scale bars: 100 μm. B) Real-time
RT-PCR showed that Grp mRNA level was dramatically enhanced in BRAFNav1.8 DRG. n = 4. *p < 0.0001 versus WT, unpaired t test. C) Validation of
Grp primers using real-time RT-PCR and a series of amounts of DRG cDNA (0.01, 0.1 and 1 μl). The reactions were specific because there were no
detectable signals when DRG cDNA was substituted with H2O (blue) or ΔRT control (red) in which reverse transcriptase was omitted. D) Melt
curve to show that Grp PCR product has a single narrow peak at 83°C.
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real-time RT-PCR and validated Grp primers, we detected
a dramatic up-regulation of Grp mRNA in BRAFNav1.8
DRGs (Figure 2B), in line with the ISH results (Figure 2A).
Grp cDNA was amplified from as low as 0.01 μl of WT
DRG cDNA while no amplification was seen when
using up to 1 μl of control samples (ΔRT) in which
reverse transcriptase was omitted (Figure 2C). The single
narrow peak at 83°C in melt curve further validated the
high quality of the reactions (Figure 2D).
Finally, Mishra and Hoon used Grp-eGFP transgenic
mice generated by GENSAT as evidence to argue for an
absence of Grp mRNA expression in DRGs. It has been
well known that transgenic eGFP mouse lines generated
by BAC engineering-based technique may not necessarily
recapitulate endogenous expression as over-expression
or an absence of eGFP expression are two frequent
problems encountered, which can be attributable to the
integration site and copy number of the transgene inthe mouse genome and the size of the genomic DNAs
used to construct the vector. Although BAC-based trans-
genic lines serve as a great tool for researchers to follow
endogenous expression of many genes, it is important
to validate the line using either functional or molecular
approaches. A common practice is to screen the trans-
genic mice derived from pronuclear injection of a BAC
vector and to identify the founder that may best mimic
the endogenous gene expression, since there are great
variations of transgene expression among the transgenic
mice. One can find more information at GENSAT website:
http://www.gensat.org/index.html about the discrepancies
between eGFP expression patterns generated by GENSAT
and those in literature. It was also not rare to see discrep-
ancies in the eGFP expression patterns for the same
gene between different mouse lines when different BAC
vectors were used. For example, two independent lines
of Grp-cre mice (KH-107 and KH-288) generated by
GENSAT exhibit distinct and overlapping expression
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sion pattern of a transgenic line cannot be considered
as valid evidence to argue for an absence of the expression
of a gene.
BNP functions independent of GRP and GRPR
If BNP-NPRA signaling depends on the activation of
GRPR by GRP, intrathecal (i.t.) BNP-elicited scratching
behavior would be lost or attenuated in Grpr knock-out
(KO) or Grp KO mice. However, we did not observe
significant difference in BNP-elicited scratching re-
sponses between Grpr KO mice and their WT littermates
(Figure 3A, 3B). Next we examined whether i.t. BNP-
induced scratching behavior could be attenuated by 77427
(Chembridge), a GRP blocker whose specificity was recently
confirmed [4]. 77427 effectively reduced i.t. GRP-induced




























































































Figure 3 BNP functions independently of GRPR. A, B) BNP (1 nmol, i.t.)
as shown in 10 min time-course (A) and total (B). n = 6. C, D) Co-injection
GRP-induced scratching behavior (C) while it had no effect on scratching b
unpaired t test. E) BNP-induced scratching behavior did not differ between
behaviors induced by i.t. injection of BNP and GRP as shown in 10 min timinduced scratching behavior was not inhibited by co-
injection of 77427 (Figure 3D). Similarly, Grp KO mice
and their WT littermates showed comparable scratching
behavior evoked by i.t. BNP (Figure 3E). These genetic
and pharmacological blockade studies demonstrate that
GRP-GRPR signaling does not act downstream of BNP
in relaying itch information. Notably, the time-course
of scratching responses evoked by i.t. BNP and GRP
differs significantly. In WT mice, i.t. BNP (1 nmol) in-
duced mild bilateral scratching behavior in the first
30 min and the scratching behavior was gradually increased
in the second 30 min during the one-hour observation
(Figure 3F, 3G). In contrast, i.t. GRP (1 nmol) induced ro-
bust scratching responses for about 10 min after injection
and the number of scratching bouts decreased gradually
within 40 min. Nonetheless, these interesting and appar-





















































induced comparable scratching behavior in WT and Grpr KO mice
of GRP inhibitor 77427 (100 nmol, i.t.) significantly blocked 1 nmol
ehavior induced by 1 nmol BNP (D). n = 5. ***p < 0.001 versus saline,
WT and Grp KO mice. n = 7–10. F, G) Comparison of scratching
e-course (F) and total (G). n = 7.
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function in the same pathway.
Intrathecal BNP inhibits inflammatory pain and
morphine analgesia
Mishra and Hoon tested a few acute pain behaviors in
Nppb−/− mice and proposed that BNP is an “itch-selective”
neuropeptide that acts as the first station in primary
afferents to activate the GRP-GRPR dedicated neuronal
pathway for itch via spinal NPRA [21]. However, BNP
and NPRA in DRG neurons have been suggested to be
a novel auto-feedback nociceptive pathway to modulate
inflammatory pain [26] and BNP is a negative regulator
of neuronal excitability in response to nociceptive stimuli
[27]. Moreover, i.t. BNP attenuated morphine analgesia
in mice [31].
We next examined the role of BNP in nociceptive
processing. Although BNP (0.04 nmol) did not alter
acute thermal pain as tested in 50°C tail-immersion
assay (Figure 4A), it significantly reduced the licking and
flinching time induced by intraplantar (i.pl.) injection of
capsaicin (Figure 4B). I.t. BNP also markedly attenuated
formalin-evoked nocifensive behavior during phase II
response (Figure 4C) and reduced morphine analgesia
(Figure 4D). These results confirm that BNP plays an


























































Figure 4 BNP inhibits inflammatory pain. A) BNP (0.04 nmol, i.t.) did no
tail-immersion assay. n = 9, p > 0.05, one-way ANOVA. B) BNP significantly r
n = 10. *p < 0.05 versus saline, unpaired t test. C) BNP (0.1 nmol, i.t.) did not ch
phase (10–60 min) of formalin pain. n = 6–7. *p < 0.05 versus saline, unpaired
injection (5 mg/kg, i.p.) significantly blocked morphine analgesic effect as test
*p < 0.05 versus pre-saline +morphine, unpaired t test.contrast, neither GRP nor GRPR is involved in morphine
analgesia [32] and both loss- and gain-of-function studies
consistently demonstrated that GRP-GRPR signaling is
not involved in nociceptive processing [2-4,32]. Therefore,
the BNP-NPRA and GRP-GRPR pathways are unlikely to
be in the same dedicated neuronal pathway for itch.
Conclusions
The present study questions the experimental approaches
that Mishra and Hoon used and the data they presented in
their studies. Specifically, we question the BNP immuno-
staining pattern in DRGs as we could not recapitulate
their results in DRG neurons using the same antibody. For
NPRA staining, we detected numerous NPRA+ neurons
in DRGs and NPRA+ fibers in the spinal cord and were
unable to detect lamina I-restricted NPRA+ neuronal stain-
ing pattern that resembles that of Grp mRNA expression
in the spinal cord. We show that BNP-NPRA signaling is
involved in both itch and pain, which contrasts with
itch-specific GRP-GRPR signaling. Given that BNP could
activate peripheral NPRA to reduce the excitability of
sensory neurons and the conflicting data on BNP expres-
sion in sensory neurons [26,27], we suggest that the
sites of action (glia vs neurons; DRGs vs spinal cord)
and the underlying mechanisms (inhibitory vs excitatory)














t alter the baseline of thermal sensation as tested in a 50°C
educed the licking and flinching time induced by capsaicin (2 μg, i.pl.).
ange the first phase (0–10 min), but significantly reduced the second
t test. D) Pre-injection of BNP (0.04 nmol, i.t.) 10 min before morphine
ed by tail-immersion assay 60 min after morphine injection. n = 6.
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by real-time RT-PCR in DRGs. More important, we dem-
onstrate that BNP-NPRA signaling does not function as
the first station upstream of the GRP-GRPR pathway
using both pharmacological and genetic approaches, the
latter of which is considered to be superior to the former.
Taken together, abundant evidence supports the notion
that GRP is indeed a primary afferent transmitter for itch
and argues against the linear BNP-NPRA-GRP-GRPR
cascade. Nevertheless, identification of BNP in itch
transmission provides an important and new avenue for
further investigating itch signaling from the pruricep-
tors to the spinal cord. The action of BNP-NPRA in itch
and pain and their relationship with GRP-GRPR signaling
require more extensive investigation.
Materials and methods
Animals
Male mice between 7 and 12 weeks old were used for the
experiments. C57BL/6 J mice were purchased from the
Jackson Laboratory. Grp KO mice, Grpr KO mice and
BRAFNav1.8 mice were used as described [2,4]. All the mice
were housed under a 12 h light/dark cycle with food and
water provided ad libitum. All the animal experiments
were performed in accordance with the guidelines of
the National Institutes of Health and the International
Association for the Study of Pain and were approved by
the Animal Studies Committee at Washington University
School of Medicine.
Immunohistochemistry and ISH
Immunohistochemical staining was performed as described
[33]. Briefly, mice were anesthetized with an overdose
of ketamine/xylazine cocktail and fixed by intracardiac
perfusion of cold 0.01 M PBS (pH 7.4) and 4% paraformal-
dehyde. Tissues were immediately removed, post-fixed
in the same fixative overnight at 4°C, and cryoprotected
in 30% sucrose PBS solution. Tissues were frozen and
sectioned at 20–25 μm thickness on a cryostat. Free-
floating sections were blocked in a solution containing
2% donkey serum and 0.3% Triton X-100 in PBS for
1 h at room temperature. The sections were incubated
with primary antibodies overnight at 4°C followed by
secondary antibodies. The following primary antibodies
were used at the specified dilutions: rabbit anti-NPRA
(1:200, LS-C109432, LifeSpan Bioscience), rabbit anti-
NPRA (1:300, ab70848, Abcam), mouse anti-BNP (1:100,
LS-C82084, LifeSpan Bioscience), mouse anti-NeuN
(1:10,000, MAB377, Millipore), and goat anti-BNP (V-17)
(1:100, sc-67455, Santa Cruz). The secondary antibodies
were purchased from Jackson ImmunoResearch Labora-
tories, Inc. including Cy3- or FITC-conjugated donkey
anti-rabbit or anti-mouse IgG (1:1,000). For the ISH study,
a digoxigenin-labeled cRNA probe was used as describedearlier [34]. Images were taken using a Nikon Eclipse Ti-U
microscope and confocal microscope (Leica TCS SPE).
Real-time RT-PCR
Real-time RT-PCR was performed as previously described
[32]. Briefly, DRGs were dissected out from 9 weeks old
male mice (n = 4 per genotype). Tissues were temporarily
stored on ice in 1 ml of RNA stabilizer (RNAlater, QIA-
GEN). Total RNA was isolated and genomic DNA was
removed in accordance with manufacturer’s instructions
(RNeasy plus mini kit; QIAGEN). RNA was quantified
using Eppendorf BioPhotometer and stored at −80°C.
Single-stranded cDNA was synthesized from 1 μg of total
RNA using High Capacity cDNA Reverse Transcription
Kit (Life Technologies) and stored at −20°C until the
analysis. Reverse transcriptase was omitted for negative
control (ΔRT). Gene expression of Grp was determined
by real-time PCR (StepOnePlus; Applied Biosystems).
Specific primers spanning intron were designed with
the NCBI Primer-BLAST. The fidelity and specificity of
the primers were validated by real-time PCR using serial
volume (1 μl, 0.1 μl and 0.01 μl) of WT DRG cDNA and
PCR efficiency (Ef) was calculated. The primers used are:
Grp (NM_175012.2, Ef = 0.8632, R2 = 0.9990): 5′-TGGG
CTGTGGGACACTTAAT-3′ (exon1); 5′-GCTTCTAGGA
GGTCCAGCAAA-3′ (exon2); amplicon size: 146 nt;
intron size: 6,158 bp.
Actb (NM_007393.3, Ef = 0.9987, R2 = 1): 5′-TGTTAC
CAACTGGGACGACA-3′ (exon3); 5′-GGGGTGTTGA
AGGTCTCAAA-3 (exon 4)′; amplicon size: 166 nt. in-
tron size: 454 bp.
Real-time PCR was carried out with FastStart Universal
SYBR Green Master (Roche Applied Science). All samples
(0.1 μl) were assayed in duplicates. Thermal cycling was
initiated with denaturation at 95°C for 10 min. After this
initial step, 40 cycles of PCR (heating at 95°C for 10 sec
and 60°C for 30 sec) were performed. Data were analyzed
using Comparative CT Method (StepOne Software v2.2.2.)
and the expression of Grp was normalized to the expres-
sion of Actb after adjustment with Ef.
Behavioral tests
Behavioral tests were videotaped (HDR-CX190, Sony) from
a side angle. The videos were played back on a computer
and the quantification of mice behaviors were done by
persons who were blinded to the treatments and genotypes.
Scratching behavior
Itch behaviors were performed as previously described
[2,3]. Briefly, prior to experiments, mice were given
30 min to acclimate to the plastic arenas (10 × 10.5 ×
15 cm). Mice were then briefly removed from the
chamber for drug injections.
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Thermal sensitivity was determined using tail immersion
assay. Mice tails were dipped beneath the warm water
(50°C) in a temperature-controlled water bath (IITC Inc.).
The latency to withdrawal was measured with a 12-sec
cutoff. For morphine analgesia study, BNP (Phoenix
Pharmaceuticals) was intrathecally injected 10 min before
morphine injection (5 mg/kg, i.p.) and tail immersion
(50°C) results were expressed as percentage of maximum
possible effect [%MPE = (post drug latency - pre drug
latency) × 100/ (cutoff time – pre drug latency)].
Acute nociceptive behavior
Algogens were intraplantarly injected into right hindpaws.
The duration of licking and flinching of the injected
paw was recorded for 60 min after injection of formalin
(2%, 20 μl) and for 5 min after injection of capsaicin
(2 μg, 20 μl).
Data analysis
All values are expressed as the means ± standard error of
the mean (S.E.M.). Statistical analysis was performed using
Prism v5.03 (GraphPad Software). p < 0.05 was considered
statistically significant.
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